ALNY Alnylam Pharmaceuticals Inc

$ALNY Alnylam plans a 2027 pivotal Huntington's study, pending regulator alignment, after one top dose cut spinal-fluid mutant huntingtin by a mean 60-64% at month 3. 🏢 Alnylam Pharmaceuticals is the RNAi drug maker behind AMVUTTRA for ATTR amyloidosis, and it is developing brezosiran for Huntington's disease with Regeneron 🏢 At a $30.41B market value ($227.28 at 16:00 ET on October 22, 2026), the stock rides on TTR drugs that sold $1,030M in Q2 2026, and Alnylam held $3.31B of cash and investments at June 30, 2026 ⚠️ The case against: these are single doses in a small early study, spinal-fluid huntingtin is a marker rather than proof of slower disease, and the 2027 start still needs regulators to agree 📅 Next: Alnylam discusses the data at its RNAi Roundtable on October 26, 2026, at 10:00 a.m. ET; watch for the pivotal design and chosen dose Source: Business Wire release, Oct 23 + SEC 8-K, Jul 30

$ALNY well… I found that alny’s competitors phase 3 failed therefore alny went down since they are similar. The Phase III CARDIO-TTRansform trial for Wainua (eplontersen) did not meet its primary efficacy endpoint of reducing cardiovascular mortality and recurrent cardiovascular events compared to placebo. AstraZeneca Trial Overview and Findings Primary Endpoint: The study evaluated adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) over a period of up to 140 weeks. Adding Wainua to the standard of care did not show a statistically